All In Biotech

Drug Trial Radar · NCT06564974

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy [SUpplemental Patient dMd assessMents Investigating ouTcomes (SUMMIT)]

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Sep 25, 2024

Primary completion

Feb 2032

Study completion Feb 2032

Sponsor

Lead sponsor
Catalyst Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
ICON plc; Veeva Systems; Children's Hospital of Eastern Ontario; Medpace, Inc.
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Male only, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of life, as assessed by standardized patient-reported outcome measures (QoL questionnaires) in male patients aged 2 years and older with Duchenne muscular dystrophy (DMD).

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • VamoroloneDrug

    Study treatment is AGAMREE®, which is commercially available as an oral suspension.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Height z-scoreTime frame: At Enrollment Visit (baseline), and at each Yearly Follow-up Visit (for up to 5 years).
  2. Change in BMI z-scoreTime frame: At Enrollment Visit (baseline), and each Yearly Follow-up Visit (for up to 5 years)
  3. Change in North Star Ambulatory Assessment from baselineTime frame: At Enrollment visit, and each Yearly Follow-up Visit (for up to 5 years).
  4. Change in Performance of Upper Limb from baselineTime frame: At Enrollment Visit, at each Yearly Follow-up Visit (for up to 5 years).
  5. Tanner stage documentationTime frame: At Enrollment Visit (baseline), at each Yearly Follow-up Visit (for up to 5 years).
  6. Percentage of patients with cataract and/or glaucomaTime frame: At Enrollment (baseline), and during each Yearly Follow-up Visit (for up to 5 years).
  7. Findings from lateral spine x-rayTime frame: At Enrollment Visit (baseline), and during each Yearly Follow-up Visit (for up to 5 years).
  8. Findings from anterior-posterior/posterior-anterior X-rayTime frame: At Enrollment Visit (baseline), and at each Yearly Follow-Up Visit (for up to 5 years).
  9. Findings from hand-wrist X-rayTime frame: At Enrollment Visit (baseline), and each Yearly Follow-Up Visit (for up to 5 years).
  10. Summary statistics of bone mineral density measures assessed by dual x-ray absorptiometryTime frame: At Enrollment Visit (baseline) and each Yearly Follow-Up Visit (for up to 5 years).
  11. Body Composition Mass MeasuresTime frame: At Enrollment Visit, each Yearly Follow-Up and End of Study/Early Termination (for approximately 5 years).
  12. Summary statistics of body fat percentage and regional fat distribution ratios assessed by DXATime frame: At Enrollment visit, each Yearly Follow-up visit, and End of study/Early termination (for approximately 5 years).
  13. Findings from standard of care echocardiographyTime frame: At Enrollment Visit, and at each Yearly Follow-up Visit (for up to 5 years).
  14. Frequency and percentage of participants experiencing any adverse events and serious adverse eventsTime frame: From informed consent, Enrollment visit, each Yearly follow-up visit, and End of Study/Early Termination (for up to 5 years).
  15. Findings from cardiac magnetic resonance imaging (subset of patients taking part in the cardiac sub-study only)Time frame: Enrollment Visit, and at each Yearly Follow-Up Visit (for up to 5 years).
  16. Presence of cardiomyopathy assessed by echocardiography using transmural strain profile (only in a subset of patients taking part in the cardiac sub-study)Time frame: At Enrollment Visit (baseline), and each Yearly Follow-up Visit (for up to 5 years) or Early Termination.

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • Arkansas Childrens Hospital

    Little Rock, Arkansas · Enrolling by invitation

  • Loma Linda University Pediatric Subspecialty Clinics

    Loma Linda, California · Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Not yet recruiting

  • Valley Children's Hospital

    Madera, California · Not yet recruiting

  • Stanford University

    Palo Alto, California · Not yet recruiting

  • University of California, Davis

    Sacramento, California · Recruiting

  • Children's National Health System

    Washington D.C., District of Columbia · Not yet recruiting

  • University of Florida Clinical and Translational Science Institue

    Gainesville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Not yet recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Enrolling by invitation

  • Nemours Children's Hospital

    Orlando, Florida · Enrolling by invitation

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida · Recruiting

  • Lurie Children's Hospital of Chicago

    Chicago, Illinois · Enrolling by invitation

  • Indiana University Health - Riley Hospital for Children

    Indianapolis, Indiana · Enrolling by invitation

  • University of Kansas Medical Center

    Kansas City, Kansas · Enrolling by invitation

  • University of Massachusetts Memorial Medical Center

    North Worcester, Massachusetts · Enrolling by invitation

  • Helen DeVos Children's Hospital

    Grand Rapids, Michigan · Enrolling by invitation

  • Masonic Children's Hospital - Discovery Clinic

    Minneapolis, Minnesota · Not yet recruiting

  • The Children's Hospital at Montefiore

    The Bronx, New York · Not yet recruiting

  • Atrium Health Neurosciences Institute

    Charlotte, North Carolina · Enrolling by invitation

  • Duke University Medical Center and Childrens Health Center

    Durham, North Carolina · Enrolling by invitation

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Penn State Milton S. Hershey Medical Center- Penn State Hershey Neuroscience Institute

    Hershey, Pennsylvania · Enrolling by invitation

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania · Enrolling by invitation

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Enrolling by invitation

  • Neurology Rare Disease Center - Neurology & Neuromuscular Care Center

    Denton, Texas · Enrolling by invitation

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas · Recruiting

  • University of Virginia Health System (UVAHS) - Pediatric Neuromuscular Center

    Charlottesville, Virginia · Enrolling by invitation

  • Seattle Children's Hospital

    Seattle, Washington · Enrolling by invitation

  • Children's Wisconsin

    Milwaukee, Wisconsin · Not yet recruiting

  • San Jorge Children's Hospital

    San Juan, Puerto Rico, Puerto Rico · Recruiting

  • FDI Clinical Research

    San Juan, Puerto Rico, Puerto Rico · Enrolling by invitation

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.